Mobotinib indications, main efficacy and effects

Mobocertinib (Mobocertinib) is mainly used to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins). This mutation accounts for about 30% of patients with non-small cell lung cancer and is often less sensitive to traditional EGFR inhibitors.

Mobotinib, as a potent small molecule tyrosine kinase inhibitor, can highly specifically target EGFR and HER2 exon 20 insertion mutations to achieve precise treatment. By inhibiting the abnormal EGFR signaling pathway, mobotinib can block the growth and reproduction of tumor cells, thereby effectively delaying the development of tumors. Clinical trial results show that mobotinib has good efficacy in the treatment of EGFR ex20ins mutant non-small cell lung cancer and can significantly improve the survival of patients. Mobotinib has relatively low side effects and is tolerated by most patients, providing the possibility for long-term treatment of patients.

According to the published cohort study results of the phase 1/2 trial, the overall response rate (ORR) of mobotinib was 28% and the disease control rate (DCR) was as high as 78%, showing good efficacy and tolerability. These data further support the important role of mobotinib in the treatment of selected patients with non-small cell lung cancer.

Mobotinib, as an innovative targeted therapy, provides a new treatment option for patients with non-small cell lung cancer who have EGFR exon 20 insertion mutations. Its high specificity, significant efficacy and good tolerability make it one of the important drugs for the treatment of such diseases. If patients have questions about mobotinib, please consult their professional attending physician.